MAPK/c-Jun signaling pathway contributes to the upregulation of the anti-apoptotic proteins Bcl-2 and Bcl-xL induced by Epstein-Barr virus-encoded BARF1 in gastric carcinoma cells

Zhang,Yuqiong; Xu,Meiqin; Zhang,Xueyi; Chu,Fuying; Zhou,Tianji

doi:10.3892/ol.2018.8293

MAPK/c-Jun signaling pathway contributes to the upregulation of the anti-apoptotic proteins Bcl-2 and Bcl-xL induced by Epstein-Barr virus-encoded BARF1 in gastric carcinoma cells

Authors:
- Yuqiong Zhang
- Meiqin Xu
- Xueyi Zhang
- Fuying Chu
- Tianji Zhou
View Affiliations

Affiliations: Department of Clinical Laboratory and Microbiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China, Department of Clinical Laboratory, Suzhou Psychiatric Hospital, Suzhou, Jiangsu 215137, P.R. China, Department of Biochemistry, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China
Published online on: March 19, 2018 https://doi.org/10.3892/ol.2018.8293
Pages: 7537-7544
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

BARF1, encoded by Epstein-Barr virus (EBV), has been hypothesized to function as an oncogene, which was expressed in gastric carcinoma cells. Additionally, it has been reported that the anti‑apoptotic function is closely associated with the expression of the B‑cell lymphoma‑2 (Bcl‑2) protein. In addition, the signaling pathway has been reported to be involved in numerous diseases, including the mitogen‑activated protein kinase (MAPK) cascade. In order to study the specific mechanism of anti‑apoptotic function, BARF1‑stably‑expressing immortalized normal human embryo gastric epithelial cell line GES1 (GES‑BARF1), and well‑, moderately‑ and poorly‑differentiated gastric carcinoma cell lines, MKN28 (which has been reported to be contaminated with the moderately‑differentiated MKN74 gastric carcinoma cell line), SGC7901 and BGC823 (MKN‑BARF1, SGC‑BARF1 and BGC‑BARF1, respectively) (GCC‑BARF1) were constructed, with transfection of cells with the empty vector pSG5 acting as controls. Western blot analysis was performed to analyze the protein expression and the phosphorylation levels. Compared with the controls, it was found that the protein expression levels of c‑Jun, Bcl‑2 and B‑cell lymphoma‑extra large (Bcl‑xL), as well as the phosphorylation levels of c‑Jun, c‑Jun N‑terminal kinase (JNK) 1/2/3, p38 and extracellular signal‑regulated kinase (ERK) 1/2 proteins were upregulated in 3 GCC‑BARF1 but not significantly changed in GES‑BARF1. The expression levels of the c‑Jun, Bcl‑2 and Bcl‑xL proteins, and levels of c‑Jun protein phosphorylation were significantly decreased in SGC‑BARF1 cells subsequent to treatment with SP600125, SB203580, and U0126, which were the specific inhibitors of JNK1/2/3, p38 and ERK1/2 respectively. In addition, there was a gradual increase in the protein expression and phosphorylation levels between normal gastric epithelial cells, and well‑differentiated, moderately‑differentiated and poorly‑differentiated gastric carcinoma cells, but this was not statistically significant. Therefore, the present study hypothesized that JNK1/2/3‑, p38‑ and ERK1/2-MAPK/c-Jun cascade signaling pathways may contribute to the upregulation of the expression of the anti‑apoptotic proteins Bcl‑2 and Bcl‑xL induced by BARF1 in gastric carcinoma cells. This mechanism may mainly work in the progressive phase of the development in EBV-associated gastric carcinoma.

View Figures

View References

1	Seto E, Yang L, Middeldorp J, Sheen TS, Chen JY, Fukayama M, Eizuru Y, Ooka T and Takada K: Epstein-Barr virus (EBV)-encoded BARF1 gene is expressed in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the absence of lytic gene expression. J Med Virol. 76:82–88. 2005. View Article : Google Scholar : PubMed/NCBI
2	Zhang Y, Ohyashiki JH, Takaku T, Shimizu N and Ohyashiki K: Transcriptional profiling of Epstein-Barr virus (EBV) genes and host cellular genes in nasal NK/T-cell lymphoma and chronic active EBV infection. Br J Cancer. 94:599–608. 2006. View Article : Google Scholar : PubMed/NCBI
3	Wang Q, Tsao SW, Ooka T, Nicholls JM, Cheung HW, Fu S, Wong YC and Wang X: Anti-apoptotic role of BARF1 in gastric cancer cells. Cancer Lett. 238:90–103. 2006. View Article : Google Scholar : PubMed/NCBI
4	Takada K: Epstein-Barr virus and gastric carcinoma. Mol Pathol. 53:255–261. 2000. View Article : Google Scholar : PubMed/NCBI
5	Klein E: The complexity of the Epstein-Barr virus infection in humans. Pathol Oncol Res. 4:3–7. 1998. View Article : Google Scholar : PubMed/NCBI
6	Rowe M, Lear AL, Croom-Carter D, Davies AH and Rickinson AB: Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol. 66:122–131. 1992.PubMed/NCBI
7	zur Hausen A, Brink AA, Craanen ME, Middeldorp JM, Meijer CJ and van den Brule AJ: Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: Expression of the transforming BARF1 gene. Cancer Res. 60:2745–2748. 2000.PubMed/NCBI
8	Wei MX, de Turenne-Tessier M, Decaussin G, Benet G and Ooka T: Establishment of a monkey kidney epithelial cell line with the BARF1 open reading frame from Epstein-Barr virus. Oncogene. 14:3073–3081. 1997. View Article : Google Scholar : PubMed/NCBI
9	Sheng W, Decaussin G, Sumner S and Ooka T: N-terminal domain of BARF1 gene encoded by Epstein-Barr virus is essential for malignant transformation of rodent fibroblasts and activation of BCL-2. Oncogene. 20:1176–1185. 2001. View Article : Google Scholar : PubMed/NCBI
10	Sheng W, Decaussin G, Ligout A, Takada K and Ooka T: Malignant transformation of Epstein-Barr virus-negative Akata cells by introduction of the BARF1 gene carried by Epstein-Barr virus. J Virol. 77:3859–3865. 2003. View Article : Google Scholar : PubMed/NCBI
11	Bai L and Wang S: Targeting apoptosis pathways for new cancer therapeutics. Annu Rev Med. 65:139–155. 2014. View Article : Google Scholar : PubMed/NCBI
12	Plotnikov A, Zehorai E, Procaccia S and Seger R: The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta. 1813:1619–1633. 2011. View Article : Google Scholar : PubMed/NCBI
13	Balmanno K and Cook SJ: Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 16:368–377. 2009. View Article : Google Scholar : PubMed/NCBI
14	Ohashi M, Fogg MH, Orlova N, Quink C and Wang F: An Epstein-Barr virus encoded inhibitor of colony stimulating factor-1 signaling is an important determinant for acute and persistent EBV infection. PLoS Pathog. 8:e10030952012. View Article : Google Scholar : PubMed/NCBI
15	Iyoda K, Sasaki Y, Horimoto M, Toyama T, Yakushijin T, Sakakibara M, Takehara T, Fujimoto J, Hori M, Wands JR and Hayashi N: Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer. 97:3017–3026. 2003. View Article : Google Scholar : PubMed/NCBI
16	Angel P, Hattori K, Smeal T and Karin M: The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell. 55:875–885. 1988. View Article : Google Scholar : PubMed/NCBI
17	Meng Q and Xia Y: c-Jun, at the crossroad of the signaling network. Protein Cell. 2:889–898. 2011. View Article : Google Scholar : PubMed/NCBI
18	Neyns B, Katesuwanasing, Vermeij J, Bourgain C, Vandamme B, Amfo K, Lissens W, DeSutter P, Hooghe-Peters E and DeGrève J: Expression of the jun family of genes in human ovarian cancer and normal ovarian surface epithelium. Oncogene. 12:1247–1257. 1996.PubMed/NCBI
19	Vleugel MM, Greijer AE, Bos R, van der Wall E and van Diest PJ: c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum Pathol. 37:668–674. 2006. View Article : Google Scholar : PubMed/NCBI
20	Eferl R, Ricci R, Kenner L, Zenz R, David JP, Rath M and Wagner EF: Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell. 112:181–192. 2003. View Article : Google Scholar : PubMed/NCBI
21	Young MR, Li JJ, Rincón M, Flavell RA, Sathyanarayana BK, Hunziker R and Colburn N: Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci USA. 96:9827–9832. 1999. View Article : Google Scholar : PubMed/NCBI
22	Eferl R, Sibilia M, Hilberg F, Fuchsbichler A, Kufferath I, Guertl B, Zenz R, Wagner EF and Zatloukal K: Functions of c-Jun in liver and heart development. J Cell Biol. 145:1049–1061. 1999. View Article : Google Scholar : PubMed/NCBI
23	Harper SJ and LoGrasso P: Signalling for survival and death in neurones: The role of stress-activated kinases, JNK and p38. Cell Signal. 13:299–310. 2001. View Article : Google Scholar : PubMed/NCBI
24	Rawal N, Parish C, Castelo-Branco G and Arenas E: Inhibition of JNK increases survival of transplanted dopamine neurons in Parkinsonian rats. Cell Death Differ. 14:381–383. 2007. View Article : Google Scholar : PubMed/NCBI
25	Adhikary G, Sun Y and Pearlman E: C-Jun NH2 terminal kinase (JNK) is an essential mediator of Toll-like receptor 2-induced corneal inflammation. J Leukoc Biol. 83:991–997. 2008. View Article : Google Scholar : PubMed/NCBI
26	Ruano D, Revilla E, Gavilán MP, Vizuete ML, Pintado C, Vitorica J and Castaño A: Role of p38 and inducible nitric oxide synthase in the in vivo dopaminergic cells' degeneration induced by inflammatory processes after lipopolysaccharide injection. Neuroscience. 140:1157–1168. 2006. View Article : Google Scholar : PubMed/NCBI
27	Lin A: Activation of the JNK signaling pathway: Breaking the brake on apoptosis. Bioessays. 25:17–24. 2003. View Article : Google Scholar : PubMed/NCBI
28	Hilberg F, Aguzzi A, Howells N and Wagner EF: c-jun is essential for normal mouse development and hepatogenesis. Nature. 365:179–181. 1993. View Article : Google Scholar : PubMed/NCBI
29	Raitano AB, Halpern JR, Hambuch TM and Sawyers CL: The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci USA. 92:11746–11750. 1995. View Article : Google Scholar : PubMed/NCBI
30	Hess P, Pihan G, Sawyers CL, Flavell RA and Davis RJ: Survival signaling mediated by c-Jun NH (2)-terminal kinase in transformed B lymphoblasts. Nat Genet. 32:201–205. 2002. View Article : Google Scholar : PubMed/NCBI
31	Milone MR, Pucci B, Bruzzese F, Carbone C, Piro G, Costantini S, Capone F, Leone A, Di Gennaro E, Caraglia M and Budillon A: Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. Cell Death Dis. 4:e6412013. View Article : Google Scholar : PubMed/NCBI
32	Zelivianski S, Spellman M, Kellerman M, Kakitelashvilli V, Zhou XW, Lugo E, Lee MS, Taylor R, Davis TL, Hauke R and Lin MF: ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer. 107:478–485. 2003. View Article : Google Scholar : PubMed/NCBI
33	Nishinaka T, Miura T, Sakou M, Hidaka C, Sasaoka C, Okamura A, Okamoto A and Terada T: Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway. Chem Biol Interact. 234:274–281. 2015. View Article : Google Scholar : PubMed/NCBI
34	Shaulian E and Karin M: AP-1 as a regulator of cell life and death. Nat Cell Biol. 4:E131–E136. 2002. View Article : Google Scholar : PubMed/NCBI
35	Li ZL, Abe H, Ueki K, Kumagai K, Araki R and Otsuki Y: Identification of c-Jun as bcl-2 transcription factor in human uterine endometrium. J Histochem Cytochem. 51:1601–1609. 2003. View Article : Google Scholar : PubMed/NCBI
36	Chen Y, Lian G, Zhang Q, Zeng L, Qian C, Chen S and Huang K: Overexpression of Bmi-1 induces the malignant transformation of gastric epithelial cells in vitro. Oncol Res. 21:33–41. 2013. View Article : Google Scholar : PubMed/NCBI